Clinical trials
Locally Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting locally advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,326 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06092086RecruitingPhase 2
Lorlatinib for first-line treatment of ALK-positive lung cancer
This trial tests a targeted pill, lorlatinib, for people with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received previous treatment for advanced disease. It aims to see how well the drug works in this setting.
Guangzhou, GuangdongAges 18 years+ - NCT06102772Recruiting
Combination immunotherapy and targeted therapy for advanced gastric cancer
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06102928Recruiting
Anlotinib plus Aumolertinib for first-line treatment of advanced EGFR-mutant lung cancer
This trial tests a combination of two targeted drugs (anlotinib and aumolertinib) as the first treatment for advanced lung cancer with a specific EGFR mutation (L858R). The goal is to see if the combination works better than standard care.
Kunming, YunnanAges 18 years+ - NCT06085664RecruitingPhase 1/Phase 2
Immunotherapy before prostate cancer surgery
This trial tests a new immunotherapy drug (REGN5678) given before surgery to men with high-risk prostate cancer that hasn't spread. The goal is to see if the drug can shrink or control the cancer before the prostate is removed.
Houston, TexasAges 18 years+ - NCT06102785Recruiting
Fruquintinib plus TAS102 for advanced stomach cancer
This trial tests a combination of two drugs, fruquintinib and TAS102, for people with advanced stomach cancer that has stopped responding to at least one prior chemotherapy. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06102759Recruiting
Study of adebrelimab and fruquintinib plus chemo for advanced stomach cancer after PD-1 failure
This trial tests a combination of two targeted drugs (adebrelimab and fruquintinib) plus chemotherapy (paclitaxel or albumin-bound paclitaxel) for people with advanced gastric or gastroesophageal junction cancer whose disease progressed after prior PD-1 antibody treatment. The goal is to see if this new combination can help when standard options have stopped working.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06070012RecruitingPhase 2
Tebentafusp for untreated metastatic uveal melanoma
This trial tests a new drug called tebentafusp for people with uveal melanoma that has spread to other parts of the body and who have not yet received any treatment for the metastatic disease. It requires a specific genetic marker (HLA-A*0201) and focuses on whether the drug can shrink or slow the growth of tumors.
Aurora, ColoradoAges 18 years+ - NCT06070740RecruitingPhase 2
Durvalumab Plus Chemo for Advanced Gastrointestinal NEC
This trial tests a combination of durvalumab (an immunotherapy drug) plus a chemotherapy called XELOX as the first treatment for advanced gastrointestinal neuroendocrine carcinoma (NEC). It aims to see if the combination works better than chemo alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT06065371RecruitingPhase 1
Sacituzumab govitecan plus capecitabine for advanced GI cancers
This trial tests a combination of two drugs—sacituzumab govitecan (targeted therapy) and capecitabine (chemotherapy)—for people with advanced stomach, colon, or pancreatic cancer that has stopped responding to standard treatments.
Detroit, MichiganAges 18 years+ - NCT06062823RecruitingPhase 2
Newer EGFR pill for advanced lung cancer with specific mutations
This trial tests a newer type of EGFR targeted therapy pill for people with advanced non-small cell lung cancer who have not had prior treatment and whose cancer has a specific genetic change called a PACC mutation. The goal is to see if the drug works well for this group.
SingaporeAges 21–99 - NCT06059495RecruitingPhase 2
Watch and wait with dostarlimab for localized stomach cancer
This trial tests a drug called dostarlimab for people with a specific type of stomach cancer that has not spread. The goal is to see if the drug can make the tumor disappear, so you might not need surgery right away.
BesançonAges 18–75 - NCT05443126RecruitingPhase 1/Phase 2
Testing a new RET drug for advanced lung cancer
This Phase 1/2 study tests lunbotinib, a new medicine that targets a specific lung-cancer change called RET. It aims to see how well it works and how safe it is for adults with advanced RET-altered non-small cell lung cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06043427RecruitingPhase 2
Testing paclitaxel and ramucirumab with or without zanidatamab for HER2+ stomach cancer
This trial tests adding a new drug (zanidatamab) to standard chemotherapy (paclitaxel and ramucirumab) for people with advanced HER2-positive stomach, gastroesophageal junction, or esophageal cancer that has worsened after previous treatment. It aims to see if the combination works better.
Calgary, AlbertaAges 18 years+ - NCT06034275RecruitingPhase 1
Study of VIP943 for CD123-positive blood cancers
This trial tests a new drug called VIP943 for people with advanced acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), or myelodysplastic syndrome (MDS) whose cancer cells have a marker called CD123. It is for those who have tried all other treatments or cannot receive them.
Birmingham, AlabamaAges 18 years+ - NCT06055439RecruitingPhase 1/Phase 2
CAR T cell therapy for GI cancers
This trial tests a new type of immunotherapy called CAR T cells that target a protein (CDH17) found on certain stomach, colon, and rectal cancers. It's designed for people whose cancer has spread and has been treated before.
Atlanta, GeorgiaAges 18–85 - NCT06050733Recruiting
Gut bacteria and immunotherapy response in solid tumors
This study looks at how the bacteria in your gut may affect how well immunotherapy works for solid cancers that have spread or cannot be removed. It focuses on people who have been on certain immunotherapy drugs (PD-1 or PD-L1 inhibitors) for at least 3 months but less than 2 years.
Galveston, TexasAges 35–75 - NCT06052683Recruiting
Comparing radiation side effects for low-risk prostate cancer
This trial compares two types of radiation therapy (SBRT and LDR brachytherapy) for men with low-risk or favorable intermediate-risk prostate cancer. The goal is to see which treatment causes fewer side effects.
Québec, QuebecAges 18 years+ - NCT06056115Recruiting
Tislelizumab for lung cancer with brain metastases
This trial tests a drug called tislelizumab for people with advanced lung adenocarcinoma that has spread to the brain but is not causing symptoms. It is for those who have not had prior treatment and whose tumors do not have certain gene changes.
Shijiazhuang, HebeiAges 18–75 - NCT06019702RecruitingPhase 1
Personalized mRNA vaccine for advanced digestive cancers
This trial tests a personalized mRNA vaccine designed to target unique markers on your cancer cells. The vaccine is made just for you based on genetic testing of your tumor. It is for people with advanced digestive system cancers who have run out of standard options.
Hangzhou, ZhejiangAges 18–75 - NCT06026657RecruitingPhase 1/Phase 2
NK cells with or without naxitamab for GD2-positive breast cancer
This trial tests a new treatment using immune cells called NK cells combined with chemotherapy (gemcitabine) and possibly naxitamab for people with a certain type of advanced breast cancer that has spread. It aims to see if this approach can help when standard treatments have stopped working.
Columbus, OhioAges 18 years+ - NCT06026800RecruitingPhase 1
Personalized mRNA vaccine plus standard treatment for advanced digestive cancers
This trial tests a personalized mRNA vaccine (iNeo-Vac-R01) given alongside standard first-line treatment for advanced digestive system cancers. The vaccine is made specifically for your tumor's unique genetic changes (neoantigens) and aims to help your immune system fight the cancer more effectively.
Hangzhou, ZhejiangAges 18–75 - NCT06008106RecruitingPhase 3
Tunlametinib pill vs chemo for advanced NRAS melanoma
This trial tests a new pill called Tunlametinib (a MEK inhibitor) compared to standard chemotherapy for people with advanced melanoma that has a specific NRAS gene change and no longer responds to immunotherapy. It aims to see if the new pill works better or is safer than chemo.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05994131RecruitingPhase 1/Phase 2
IN10018 plus targeted therapy for EGFR-mutant lung cancer
This trial tests a new drug called IN10018 combined with a targeted therapy (third-generation EGFR-TKI) for people with advanced EGFR-mutant non-small cell lung cancer. It's designed for different stages of treatment, from first-time therapy to after other treatments have stopped working.
ShanghaiAges 18 years+ - NCT05984810RecruitingPhase 2
Using a glowing dye to help see pancreatic cancer during surgery
This trial tests whether a special dye (SGM-101) can help surgeons see remaining cancer cells during surgery for pancreatic cancer that has been treated before surgery. It may lead to more complete removal of the tumor.
LeidenAges 18 years+
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 3,326 recruiting locally advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Solid Tumor
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.